Overview
NICE is unable to make a recommendation on eculizumab (Soliris) for treating refractory myasthenia gravis because Alexion Pharma UK did not provide an evidence submission.
Last reviewed: 30 June 2020
Next review: We will review this decision if the company decides to make a submission.